Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit ac
(Financial Post, 2025-10-22T05:01:15Z)